Prescriber adoption of newly approved selective COX-2 inhibitors.
-
Author
-
Cite
Pharmacoepidemiol Drug Safety. 2008 Dec;17(12):1168-74
Adverse drug reactions: Neuropsychiatric drug reactions associated with varenicline (Champix).
-
Author
-
Cite
The Pharmaceutical Journal. June 2008
Developing tools for the safety specification in risk management plans: lessons learned from a pilot project.
-
Author
-
Cite
Pharmacoepidemiol Drug Saf. 2008 May;17(5):445-54
Prescription Event Monitoring in the United Kingdom
-
Author
-
Cite
Pharmacoepidemiology and Therapeutic Risk Management. April 2008
European commission consultation on pharmacovigilance
-
Author
-
Cite
Pharmacoepidemiol Drug Saf. 2008 Feb;17(2):108-9
Safety profile of esomeprazole : results of a prescription-event monitoring study of 11 595 patients in England.
-
Author
-
Cite
Drug Safety. 2008;31(4):313-23
Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
-
Author
-
Cite
Drug Saf. 2008;31(2):143-58
Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England.
-
Author
-
Cite
Drug Safety. 2008;31(10):839-50
Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study.
-
Author
-
Cite
Acta Diabetol. 2007 Dec;44(4):233-9
The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
-
Author
-
Cite
Obesity. 2007 Nov;15(11):2712-22
A modified prescription-event monitoring study to assess the introduction of Flixotide Evohaler into general practice in England: an example of pharmacovigilance planning and risk monitoring.
-
Author
-
Cite
Pharmacoepidemiol Drug Saf. 2007 Sep;16(9):969-78
The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England.
-
Author
-
Cite
J Psychopharmacol. 2007 Jun;21(4):392-9
An analysis of the exclusion criteria used in observational pharmacoepidemiological studies
-
Author
-
Cite
Pharmacoepidemiol Drug Saf. 2007 Mar;16(3)
An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease.
-
Author
-
Cite
BJU Int. 2007 Feb;99(2):387-93
Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.
-
Author
-
Cite
Drug Saf. 2007;30(5):419-29
Safety profile of rosuvastatin : results of a prescription-event monitoring study of 11 680 patients
-
Author
-
Cite
Drug Saf. 2007;30(2):157-70
Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance
-
Author
-
Cite
Drug Saf. 2007;30(4):333-46.
Thoughts on signal detection in pharmacovigilance
-
Author
-
Cite
Drug Saf. 2007;30(7):603-6
A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance.
-
Author
-
Cite
Drug Safety. 2007;30(8):681-95.
Safety profile of orlistat: results of a prescription-event monitoring study
-
Author
-
Cite
Int J Obes (Lond). 2006 Nov;30(11):1645-52
Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes
-
Author
-
Cite
J Clin Psychiatry. 2006 Aug;67(8):1280-4
Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction
-
Author
-
Cite
BJU Int. 2006 Jul;98(1):125-31
Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study
-
Author
-
Cite
Acta Diabetol. 2006 May;43(1):6-13
Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England
-
Author
-
Cite
Drug Saf. 2006;29(2):151-60
Under-reporting of adverse drug reactions : a systematic review
-
Author
-
Cite
Drug Saf. 2006;29(5):385-96.